Mode
Text Size
Log in / Sign up

Hematology

108 published articles · Updated continuously

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Acute cellular senescence facilitates tissue repair while chronic accumulation drives intestinal fibrosis in Crohn's disease
Hematology Sys. Review
Acute cellular senescence facilitates tissue repair while chronic accumulation drives intestinal fibrosis in Crohn's disease Chronic cell aging may drive scarring in Crohn's disease
This systematic review examines the role of cellular senescence in intestinal fibrosis within Crohn's disease. The authors conclude that acu…
New research reveals how the timing of cellular aging determines whether your body heals properly or develops harmful scar tissue.
FDA Approves Argatroban in Sodium Chloride for Thrombosis in HIT and PCI
Hematology FDA Approval
FDA Approves Argatroban in Sodium Chloride for Thrombosis in HIT and PCI FDA approves new blood thinner for patients with rare clotting disorder.
The FDA approved argatroban in sodium chloride injection for prophylaxis or treatment of thrombosis in adult patients with heparin-induced t…
The FDA approved Argatroban in Sodium Chloride injection to prevent or treat blood clots in adults with heparin-induced thrombocytopenia (HI…
FDA Approves Hympavzi (marstacimab) for Routine Prophylaxis in Hemophilia A and B Without Inhibitors
Hematology FDA Approval
FDA Approves Hympavzi (marstacimab) for Routine Prophylaxis in Hemophilia A and B Without Inhibitors FDA approves Hympavzi to prevent bleeding in hemophilia A and B.
The FDA approved Hympavzi (marstacimab) for routine prophylaxis to prevent or reduce bleeding episodes in patients 12 years and older with h…
The FDA approved Hympavzi (marstacimab) to prevent or reduce bleeding episodes in people 12 and older with hemophilia A or B without inhibit…
OTUD7B acts as a context-dependent regulator in various cancers and inflammatory conditions
Hematology Sys. Review
OTUD7B acts as a context-dependent regulator in various cancers and inflammatory conditions Protein OTUD7B plays complex roles in cancer and heart health
This systematic review examines the molecular roles of OTUD7B across multiple malignancies and inflammatory models. The findings indicate th…
A protein called OTUD7B acts as a double-edged sword, helping some conditions while fueling the growth of others.
Anatomical and immunological factors drive pathogenesis in plasma cell mastitis cases
Hematology Sys. Review
Anatomical and immunological factors drive pathogenesis in plasma cell mastitis cases New insights into the causes and treatment of mastitis
This narrative review synthesizes the etiology, clinical manifestations, and treatment strategies for plasma cell mastitis. It highlights ho…
Doctors are identifying how structural issues and immune responses lead to chronic inflammation in breast tissue, helping clarify treatment …
Precision diagnostics and novel biomarkers improve the management of graft-versus-host disease clinical spectrum
Hematology Guideline
Precision diagnostics and novel biomarkers improve the management of graft-versus-host disease clinical spectrum New guidelines clarify treatment and diagnosis for graft-versus-host disease
This guideline provides a comprehensive overview of the graft-versus-host disease (GVHD) landscape, including acute and chronic forms. It sy…
New clinical guidelines offer a clearer look at how doctors can identify and treat the complex complications of graft-versus-host disease.
7-day venetoclax with intensive chemotherapy achieves 90.3% composite complete remission in AML
Hematology RCT
7-day venetoclax with intensive chemotherapy achieves 90.3% composite complete remission in AML Trial shows venetoclax combined with chemotherapy for AML
This clinical trial of 259 newly diagnosed patients with acute myeloid leukemia found a 90.3% composite complete remission rate using a 7-da…
A new clinical trial shows that a short 7-day course of venetoclax combined with chemotherapy can achieve high remission rates in AML patien…
Proximal gastrectomy offers shorter operative time but similar survival vs total gastrectomy in advanced gastric cancer
Hematology Meta-analysis
Proximal gastrectomy offers shorter operative time but similar survival vs total gastrectomy in advanced gastric cancer Proximal Gastrectomy May Be Safe Option for Advanced Stomach Cancer
This systematic review and meta-analysis of propensity score-matched studies compared proximal gastrectomy (PG) to total gastrectomy (TG) in…
For patients with advanced stomach cancer after chemo, keeping part of the stomach may be as safe as removing it entirely, with similar surv…
Ianalumab plus eltrombopag extends time to treatment failure in primary ITP adults
Hematology RCT
Ianalumab plus eltrombopag extends time to treatment failure in primary ITP adults Study tests ianalumab plus eltrombopag for adults with immune thrombocytopenia
This phase 3 randomized, double-blind trial in 152 adults with primary ITP and insufficient response to glucocorticoids found that ianalumab…
Adding ianalumab to standard therapy helped more adults with immune thrombocytopenia stay stable and avoid treatment failure compared to pla…
Platelet-derived DKK1 enhances leukocyte-platelet aggregation and recruits immune cells in Leishmaniasis models
Hematology Sys. Review
Platelet-derived DKK1 enhances leukocyte-platelet aggregation and recruits immune cells in Leishmaniasis models Platelet protein may help fight Leishmaniasis in mice
This review examines the role of platelet-derived DKK1 in Leishmaniasis using BALB/c mice. The authors report enhanced leukocyte-platelet ag…
A review suggests a platelet protein could help the immune system fight Leishmaniasis by recruiting helpful cells and limiting parasite surv…
FDA Approves Ultomiris (ravulizumab-cwvz) for Generalized Myasthenia Gravis
Hematology FDA Approval
FDA Approves Ultomiris (ravulizumab-cwvz) for Generalized Myasthenia Gravis FDA approves Ultomiris for adults with a form of myasthenia gravis.
The FDA approved Ultomiris (ravulizumab-cwvz) for adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine recepto…
The FDA approved Ultomiris (ravulizumab-cwvz) for adults with generalized myasthenia gravis who have a specific antibody. This drug helps bl…
Zanubrutinib Delivers High Response Rates And Survival Benefits Across Diffuse Large B-Cell Lymphoma Patient Groups In This Meta-Analysis
Hematology Meta-analysis
Zanubrutinib Delivers High Response Rates And Survival Benefits Across Diffuse Large B-Cell Lymphoma Patient Groups In This Meta-Analysis Zanubrutinib shows high response rates in diffuse large B-cell lymphoma patients
A meta-analysis of 1,346 patients with diffuse large B-cell lymphoma shows zanubrutinib achieves high response rates and prolonged survival.…
Zanubrutinib helped 95 out of 100 previously untreated patients with diffuse large B-cell lymphoma respond to treatment in this analysis.

All Hematology Articles